Bristol-Myers Squibb Co (BMY)
49.00
-0.14
(-0.28%)
USD |
NYSE |
Apr 23, 16:00
49.02
+0.02
(+0.04%)
After-Hours: 20:00
Bristol-Myers Squibb Research and Development Expense (Quarterly): 2.478B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.478B |
| September 30, 2023 | 2.242B |
| June 30, 2023 | 2.258B |
| March 31, 2023 | 2.321B |
| December 31, 2022 | 2.51B |
| September 30, 2022 | 2.418B |
| June 30, 2022 | 2.321B |
| March 31, 2022 | 2.26B |
| December 31, 2021 | 2.518B |
| September 30, 2021 | 2.98B |
| June 30, 2021 | 2.478B |
| March 31, 2021 | 2.219B |
| December 31, 2020 | 3.75B |
| September 30, 2020 | 2.499B |
| June 30, 2020 | 2.522B |
| March 31, 2020 | 2.372B |
| December 31, 2019 | 2.097B |
| September 30, 2019 | 1.378B |
| June 30, 2019 | 1.325B |
| March 31, 2019 | 1.348B |
| December 31, 2018 | 1.367B |
| September 30, 2018 | 1.28B |
| June 30, 2018 | 2.435B |
| March 31, 2018 | 1.25B |
| December 31, 2017 | 1.925B |
| Date | Value |
|---|---|
| September 30, 2017 | 1.561B |
| June 30, 2017 | 1.679B |
| March 31, 2017 | 1.303B |
| December 31, 2016 | 1.472B |
| September 30, 2016 | 1.138B |
| June 30, 2016 | 1.266B |
| March 31, 2016 | 1.136B |
| December 31, 2015 | 1.916B |
| September 30, 2015 | 1.132B |
| June 30, 2015 | 1.856B |
| March 31, 2015 | 1.016B |
| December 31, 2014 | 1.189B |
| September 30, 2014 | 983.00M |
| June 30, 2014 | 1.416B |
| March 31, 2014 | 946.00M |
| December 31, 2013 | 957.00M |
| September 30, 2013 | 893.00M |
| June 30, 2013 | 951.00M |
| March 31, 2013 | 930.00M |
| December 31, 2012 | 1.082B |
| September 30, 2012 | 951.00M |
| June 30, 2012 | 962.00M |
| March 31, 2012 | 909.00M |
| December 31, 2011 | 1.008B |
| September 30, 2011 | 973.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.325B
Minimum
Jun 2019
3.75B
Maximum
Dec 2020
2.366B
Average
2.372B
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.534B |
| Gilead Sciences Inc | 1.408B |
| Johnson & Johnson | 3.542B |
| Karuna Therapeutics Inc (DELISTED) | 82.19M |
| 2seventy bio Inc | 51.22M |